162 related articles for article (PubMed ID: 38347759)
1. Optimal follow-up schedule for patients taking PCSK9 monoclonal antibodies in a health system: Analysis of specialty pharmacy clinical interventions.
Avlasevich V; Pilat S; Reindel K; Manou K; Trawinski A; Rightmier E
Am J Health Syst Pharm; 2024 Jun; 81(13):e358-e364. PubMed ID: 38347759
[TBL] [Abstract][Full Text] [Related]
2. Incorporating diversity, equity, and inclusion concepts in pharmacy education and experiential training.
Yang T; Linn BS; Bennis J
Am J Health Syst Pharm; 2024 Apr; 81(8):275-278. PubMed ID: 37966508
[No Abstract] [Full Text] [Related]
3. LGBTQ+ applicant outreach as a metric of residency diversity.
Jacisin TC; Miller X
Am J Health Syst Pharm; 2024 Apr; 81(8):263-264. PubMed ID: 37847772
[No Abstract] [Full Text] [Related]
4. A fine line: The delicate balance between humility and self-confidence.
Vest TA; Ivey MF; Musch KLE; Tyler L
Am J Health Syst Pharm; 2024 Mar; 81(6):168-170. PubMed ID: 37879865
[No Abstract] [Full Text] [Related]
5. Timing of the initial assay for stability studies.
McPherson T; Kolling W; Navarre E
Am J Health Syst Pharm; 2024 Mar; 81(7):e156. PubMed ID: 37947169
[No Abstract] [Full Text] [Related]
6. Response to authors on LGBTQ+ applicant outreach as a metric of residency diversity.
Calabrese S
Am J Health Syst Pharm; 2024 Apr; 81(8):264. PubMed ID: 37850686
[No Abstract] [Full Text] [Related]
7. Toward collaborative practice, not collaborative practice agreements.
Adams AJ; Eid DD
Am J Health Syst Pharm; 2024 Mar; 81(7):e157-e158. PubMed ID: 37948606
[No Abstract] [Full Text] [Related]
8. Implementation of a New Clinic-Based, Pharmacist-Managed PCSK9 Inhibitor Consultation Service.
Atanda A; Shapiro NL; Stubbings J; Groo V
J Manag Care Spec Pharm; 2017 Sep; 23(9):918-925. PubMed ID: 28854074
[TBL] [Abstract][Full Text] [Related]
9. Effect of proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies on new-onset diabetes mellitus and glucose metabolism: A systematic review and meta-analysis.
Cao YX; Liu HH; Dong QT; Li S; Li JJ
Diabetes Obes Metab; 2018 Jun; 20(6):1391-1398. PubMed ID: 29377473
[TBL] [Abstract][Full Text] [Related]
10. Implementing services for pediatric cystic fibrosis treatment in a community hospital.
Grube P; Nichols H; Ferrell S; Gilham D; Gaylor A; Dunkelberger K
Am J Health Syst Pharm; 2024 Mar; 81(6):219-225. PubMed ID: 37982450
[TBL] [Abstract][Full Text] [Related]
11. Persistence and Adherence to PCSK9 Inhibitor Monoclonal Antibodies Versus Ezetimibe in Real-World Settings.
Muntner P; Ghazi L; Jones J; Dhalwani N; Poudel B; Wen Y; Chen L; Wang Z; Bittner V; Kalich B; Farkouh ME; Woodward M; Colantonio LD; Rosenson RS
Adv Ther; 2024 Jun; 41(6):2399-2413. PubMed ID: 38691317
[TBL] [Abstract][Full Text] [Related]
12. Exploring rates of PCSK9 inhibitor persistence and reasons for treatment non-persistence in an integrated specialty pharmacy model.
Donald DR; Reynolds VW; Hall N; DeClercq J; Choi L
J Clin Lipidol; 2022; 16(3):315-324. PubMed ID: 35367164
[TBL] [Abstract][Full Text] [Related]
13. Integrated specialty pharmacy yields high PCSK9 inhibitor access and initiation rates.
Reynolds VW; Chinn ME; Jolly JA; Kelley TN; Peter ME; Choi L; Nwosu S; Leon BC; Zuckerman AD
J Clin Lipidol; 2019; 13(2):254-264. PubMed ID: 30745204
[TBL] [Abstract][Full Text] [Related]
14. Health-system specialty pharmacist intervention types, acceptance, and associated actions for patients with multiple sclerosis.
El-Khouri AC; Giavatto C; Hickman A; Fitzpatrick C; Mourani J; Tiger K; Rees M; Lopez-Medina AI
Am J Health Syst Pharm; 2024 May; 81(Supplement_2):S29-S39. PubMed ID: 38298009
[TBL] [Abstract][Full Text] [Related]
15. Long-term safety and effectiveness of alirocumab and evolocumab in familial hypercholesterolemia (FH) in Belgium.
Snel M; Descamps OS
Acta Cardiol; 2024 May; 79(3):311-318. PubMed ID: 37767917
[No Abstract] [Full Text] [Related]
16. Comparing PCSK9 Monoclonal Antibody Treatment Strategies Following Myocardial Infarction Using Negative Control Outcomes: A Target Trial Emulation Study.
Sloot R; Breskin A; Colantonio LD; Allmon AG; Yu Y; Sakhuja S; Chen L; Muntner P; Brookhart MA; Dhalwani N
Epidemiology; 2024 Jul; 35(4):579-588. PubMed ID: 38629975
[TBL] [Abstract][Full Text] [Related]
17. Association Between Circulating Baseline Proprotein Convertase Subtilisin Kexin Type 9 Levels and Efficacy of Evolocumab.
Desai NR; Giugliano RP; Wasserman SM; Gibbs JP; Liu T; Scott R; Sabatine MS
JAMA Cardiol; 2017 May; 2(5):556-560. PubMed ID: 28122070
[TBL] [Abstract][Full Text] [Related]
18. Vaccines Targeting PCSK9: A Promising Alternative to Passive Immunization with Monoclonal Antibodies in the Management of Hyperlipidaemia?
Weisshaar S; Zeitlinger M
Drugs; 2018 Jun; 78(8):799-808. PubMed ID: 29737499
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic efficacy of PCSK9 monoclonal antibodies in statin-nonresponsive patients with hypercholesterolemia and dyslipidemia: A systematic review and meta-analysis.
Peng W; Qiang F; Peng W; Qian Z; Ke Z; Yi L; Jian Z; Chongrong Q
Int J Cardiol; 2016 Nov; 222():119-129. PubMed ID: 27494723
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
